Getting to the Heart of the Matter: A Review of Drug Interactions Between HIV Antiretrovirals and Cardiology Medications

被引:18
|
作者
Giguere, Pierre [1 ]
Nhean, Salin [2 ,3 ]
Tseng, Alice L. [4 ]
Hughes, Christine A. [5 ]
Angel, Jonathan B. [6 ]
机构
[1] Ottawa Hosp Res Inst, Ottawa Hosp, Dept Pharm, Ottawa, ON, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[4] Univ Toronto, Univ Hlth Network, Leslie Dan Fac Pharm, Toronto, ON, Canada
[5] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada
[6] Univ Ottawa, Fac Med, Ottawa Hosp Res Inst, Ottawa, ON, Canada
关键词
ORGANIC ANION TRANSPORTERS; PHARMACOKINETIC INTERACTIONS; QT INTERVAL; CLINICAL PHARMACOKINETICS; INFECTED PATIENTS; PROTEASE INHIBITORS; POSITIVE PATIENTS; DIGOXIN TOXICITY; RISK-FACTORS; RITONAVIR;
D O I
10.1016/j.cjca.2018.12.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The past 20 years have seen remarkable advances in the treatment of HIV such that most people diagnosed with HIV today can live long, healthy lives by taking antiretrovirals which are usually life-long. Advancements in antiretroviral therapy include the availability of well tolerated, single tablet regimens that are associated with a lower risk of drug-drug interactions. Despite this, many people living with HIV infection might be taking antiretroviral agents that are associated with significant drug-drug interactions. Because HIV infection itself is associated with cardiovascular complications and this population is living longer, concomitant use of antiretrovirals and medications to treat cardiovascular-related diseases is often required. For this reason, it is imperative that clinicians are aware of the potential for clinically significant drug-drug interactions between antiretroviral agents and cardiac medications as well as the useful HIV drug interaction resources that might provide guidance. Available data on significant interactions are summarized and suggested guidance regarding management is discussed.
引用
收藏
页码:326 / 340
页数:15
相关论文
共 43 条
  • [31] Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management
    MacDougall, Conan
    Canonica, Theora
    Keh, Chris
    P. Phan, Binh An
    Louie, Janice
    PHARMACOTHERAPY, 2022, 42 (04): : 343 - 361
  • [32] Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients
    Jakeman, Bernadette
    Nasiri, Mona
    Ruth, Lindsey
    Morse, Caroline
    Mahatme, Sheran
    Patel, Nimish
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (05) : 365 - 372
  • [33] Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review
    Plasencia-Garcia, Beatriz Oda
    Rodriguez-Menendez, Gonzalo
    Rico-Rangel, Maria Isabel
    Rubio-Garcia, Ana
    Torello-Iserte, Jaime
    Crespo-Facorro, Benedicto
    PSYCHOPHARMACOLOGY, 2021, 238 (02) : 329 - 340
  • [34] Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort
    Lewis, J. M.
    Stott, K. E.
    Monnery, D.
    Seden, K.
    Beeching, N. J.
    Chaponda, M.
    Khoo, S.
    Beadsworth, M. B. J.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2016, 27 (02) : 105 - 109
  • [35] Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia
    Aouri, Manel
    Decosterd, Laurent A.
    Buclin, Thierry
    Hirschel, Bernard
    Calmy, Alexandra
    Livio, Francoise
    AIDS, 2012, 26 (06) : 776 - 778
  • [36] Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia
    Toy, Junine
    Giguere, Pierre
    Kravcik, Stephen
    la Porte, Charles J. L.
    AIDS, 2011, 25 (04) : 541 - 542
  • [37] Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers
    Akshanth R. Polepally
    Jennifer R. King
    Bifeng Ding
    Diana L. Shuster
    Emily O. Dumas
    Amit Khatri
    Yi-Lin Chiu
    Thomas J. Podsadecki
    Rajeev M. Menon
    Clinical Pharmacokinetics, 2016, 55 : 1003 - 1014
  • [38] Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors
    Khatri, Amit
    Dutta, Sandeep
    Wang, Haoyu
    Podsadecki, Thomas
    Trinh, Roger
    Awni, Walid
    Menon, Rajeev
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (08) : 972 - 979
  • [39] Mini-review: Elucidating the psychological, physical, and sex-based interactions between HIV infection and stress
    Stadtler, Hannah
    Shaw, Gladys
    Neigh, Gretchen N.
    NEUROSCIENCE LETTERS, 2021, 747
  • [40] Potential Interactions Between HIV Drugs, Ritonavir and Efavirenz and Anticancer Drug, Nilotinib-A Study in Primary Cultures of Human Hepatocytes That Is Applicable to HIV Patients With Cancer
    Pillai, Venkateswaran C.
    Parise, Robert A.
    Christner, Susan M.
    Rudek, Michelle A.
    Beumer, Jan H.
    Venkataramanan, Raman
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (11) : 1272 - 1279